Galecto to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Galecto Inc (NASDAQ: GLTO), a clinical-stage biotechnology company developing treatments for cancer and severe liver diseases, has announced its participation in three major upcoming investor conferences.

The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 8:40-9:10 AM in a virtual format, featuring both a corporate presentation and one-on-one meetings. A live webcast will be available on Galecto's investor relations website, with replay access for 90 days.

Additionally, Galecto will attend the Leerink Partners Global Healthcare Conference on March 12 in Miami Beach, Florida, conducting one-on-one meetings, and the 37th Annual ROTH Conference on March 17-18 in Dana Point, CA, where they will deliver a corporate presentation and hold one-on-one meetings.

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences:

Oppenheimer 35th Annual Healthcare Life Sciences Conference
Format: Corporate Presentation and One-on-One Meetings
Date and Time: Wednesday, February 12 at 8:40-9:10 AM  
Location: Virtual

A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 90 days following the event.

Leerink Partners Global Healthcare Conference
Format: One-on-One meetings
Date and Time: Wednesday, March 12
Location: Miami Beach, Florida

37th Annual ROTH Conference
Format: Corporate Presentation and One-on-One Meetings
Date and Time: Monday, March 17, and Tuesday, March 18
Location: Dana Point, CA

About Galecto

Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) as recently announced, a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML, which Galecto acquired from Bridge Medicines. Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Investors Contact:

Sandya von der Weid

svonderweid@lifesciadvisors.com

+41 78 680 0538

FAQ

When and where is Galecto (GLTO) presenting at the Oppenheimer Healthcare Conference 2025?

Galecto will present virtually at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 8:40-9:10 AM.

How long will the GLTO Oppenheimer Conference webcast replay be available?

The webcast replay will be accessible for 90 days following the event through Galecto's investor relations website.

Which investor conferences is Galecto (GLTO) attending in March 2025?

Galecto is attending the Leerink Partners Global Healthcare Conference in Miami Beach on March 12 and the 37th Annual ROTH Conference in Dana Point, CA on March 17-18.

Where can investors access Galecto's (GLTO) Oppenheimer Conference presentation webcast?

Investors can access the live webcast through the Upcoming Events section of Galecto's investor relations website at https://ir.galecto.com/news-and-events/events.